*ST恆康(002219.SZ)擬轉讓大連遼漁醫院100%出資人權益
格隆匯 12 月 2日丨*ST恆康(002219.SZ)公佈,為了緩解公司資金壓力,補充公司流動資金,公司於2020年12月1日召開第五屆董事會第三十六次會議,審議通過了《關於轉讓大連遼漁醫院出資人權益的議案》,同意公司轉讓其持有的大連遼漁醫院100%的出資人權益及與之相關的全部權益(“標的權益”)。標的權益的轉讓價格參考評估報告並經雙方協商確定,標的權益轉讓價格為9000萬元人民幣。
此次權益轉讓完成後,公司將不再持有交易標的權益,交易標的將不再納入公司合併報表範圍,此次交易將對公司當期淨利潤影響約為8000萬元,最終數據以審計為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.